155 related articles for article (PubMed ID: 19638887)
1. Fesoterodine for the treatment of overactive bladder.
Belavic JM
Nurse Pract; 2009 Aug; 34(8):14-5. PubMed ID: 19638887
[No Abstract] [Full Text] [Related]
2. Fesoterodine (toviaz) for overactive bladder.
Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
[No Abstract] [Full Text] [Related]
3. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
4. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
5. Early onset of fesoterodine efficacy in subjects with overactive bladder.
Goldman HB; Morrow JD; Gong J; Tseng LJ; Schneider T
BJU Int; 2011 Feb; 107(4):598-602. PubMed ID: 20868387
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
[TBL] [Abstract][Full Text] [Related]
7. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
8. Durability of treatments for overactive bladder.
Dasgupta P
Int J Clin Pract; 2010 Apr; 64(5):528-9. PubMed ID: 20456203
[No Abstract] [Full Text] [Related]
9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
10. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.
Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Choo MS
BJU Int; 2011 Feb; 107(4):603-11. PubMed ID: 20860648
[TBL] [Abstract][Full Text] [Related]
11. New drug information: Toviaz.
Physician Assistants' Prescribing Reference
JAAPA; 2009 Jun; 22(6):12. PubMed ID: 19601442
[No Abstract] [Full Text] [Related]
12. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
13. Tolterodine for treatment of overactive bladder.
Kanofsky JA; Nitti VW
Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
15. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
16. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
Van Kerrebroeck PE; Heesakkers J; Berriman S; Padmanabhan Aiyer L; Carlsson M; Guan Z
Int J Clin Pract; 2010 Apr; 64(5):584-93. PubMed ID: 20201992
[TBL] [Abstract][Full Text] [Related]
17. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
18. [More quality of life again with tolterodine].
Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
[No Abstract] [Full Text] [Related]
19. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
20. Editorial comment.
de Jong TP
J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
